Share on StockTwits
 

RTI Biologics (NASDAQ:RTIX) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research note issued on Monday, StockRatingsNetwork.com reports. They currently have a $3.40 price target on the stock. Zacks‘ price objective suggests a potential downside of 4.76% from the company’s current price.

RTI Biologics (NASDAQ:RTIX) traded up 0.56% on Monday, hitting $3.57. 511,103 shares of the company’s stock traded hands. RTI Biologics has a 52-week low of $2.77 and a 52-week high of $4.53. The stock’s 50-day moving average is $3.29 and its 200-day moving average is $3.37. The company’s market cap is $201.3 million.

RTI Biologics (NASDAQ:RTIX) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The company had revenue of $60.50 million for the quarter, compared to the consensus estimate of $59.20 million. During the same quarter in the previous year, the company posted $0.04 earnings per share. The company’s revenue for the quarter was up 35.7% on a year-over-year basis. Analysts expect that RTI Biologics will post $0.04 EPS for the current fiscal year.

Separately, analysts at Canaccord Genuity raised their price target on shares of RTI Biologics from $3.50 to $4.00 in a research note on Friday.

RTI Biologics, Inc process human musculoskeletal and other tissue. It also processes bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE and TUTOPLAST sterilization processes, for distribution to hospitals and surgeons.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.